Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia ...

A Surprising Marker: The Ovarian Cancer Clue In a twist no one expected, researchers found that many HV tumors express CA125, a marker known for its role in ovarian cancer. This means that 1 in 4 ...

Even so, 30% of people with bladder cancer have no identifiable risk. Fortunately for you, a noninvasive cancer was found that was less than 3 cm, which is the best possible result for bladder cancer.

A research team led by Professor Lee Sang-chul of the Department of Urology at Seoul National University Bundang Hospital ...

The U.S. Food and Drug Administration has approved UGN-102 (mitomycin intravesical solution) for the treatment of adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder ...

The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's drug to treat a type of bladder cancer, providing an alternative treatment as opposed to traditional surgical procedures.

The disease, a type of non-muscle invasive bladder cancer, affects about 82,000 people in the U.S. each year, with around 59,000 experiencing a recurrence, according to UroGen.

Yang, H., et al. (2025). Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nature Communications. doi.org/10.1038/s41467-025-59888-8.

Lymph Node-positive Bladder Cancer Surgical, Pathologic, Molecular and Prognostic Aspects Jose A Pedrosa; Michael O Koch; Liang Cheng Disclosures Expert Rev Anticancer Ther. 2013;13 (11):1281-1295.

Treatment recommendations for all stages of bladder cancer have been proposed in the form of clinical guidelines from the European Association of Urology and the American Urological Association ...

UroGen Pharma shares surged after the company received Food and Drug Administration approval for bladder cancer drug Zusduri, previously known as UGN-102. The stock was recently up 36% to $9.96.

Lacey Parker discusses her journey with recurrent LG-IR-NMIBC. Background information on Bladder Cancer and NMIBC. ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent ...